Neuron23 combines advances in human genetics with a drug discovery and biomarker platform using advanced techniques in machine learning and artificial intelligence to advance therapeutics for diseases. The USA-based company’s focus areas are neurodegenerative diseases, neuroinflammatory diseases, and systemic autoimmune and inflammatory diseases.